Cancer sales boost Russia's Pharmstandard by 84%

Leading Russian drugmaker Pharmstandard saw third quarter sales leap by 84% to 14.7 billion roubles ($469.3 million), thanks to a new government purchases of cancer drugs. Johnson & Johnson's ($JNJ) Velcade accounted for one-third of that revenue, at 4.8 billion roubles, or $153 million. Report

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…